Neuland Laboratories Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kdaneq7t38xursq5dks663e0.pdf

Key Takeaways


Business Model Transition & Margin Profile

Saharsh Davuluri: "I think we have left our commentary using the same words, right I think normalized margins and moderate growth. I think it's something that we intentionally are using words and not numbers and we are not intentionally referring to any past performance."

Segment Performance


Biosecure Act: Promise vs. Present Reality

Saharsh Davuluri: "I think it's very evident in whatever conversations even I've had with US customers that they are looking at an alternative to China, whether or not the Biosecure Act gets implemented in its current draft or not. So, there is business to come. It just remains to be seen how much and when."

Capacity Expansion & Investment Phase

Saharsh Davuluri: "We also want to make sure that capacity is being created in anticipation of some specific demand rather than create a very large facility and then look for customers. I think that is not an approach that we believe works for the kind of APIs we are pursuing in CMS as well as GDS."

Pipeline & Future Growth Levers

Sucheth Davuluri: "I think the reason we made that comment is because year-to-year we grew 30%. And the year before that, the growth was about 24% year-on-year. So, I think for us, it was important to come out and say that that's the kind of growth that we cannot expect year-on-year."

Risk Management & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
Unit-3 new production blocksCommercial production to beginH2 FY26
FY25 outlookYear of modest growth and normalized margins; consolidation influenced by product lifecycle dynamicsFY25
Growth momentum returnBusinesses to regain momentum based on current portfolio visibilityFrom FY26
Big Pharma engagement parityExpect Big Pharma to have similar comfort level as current biotech clients2-3 years
Difelikefalin commercializationPeptide molecule for chronic kidney disordersPost-2030
CMS molecules in Unit-3Flow into Unit-3 at different stagesSome in FY26, some in FY27

Key Metrics

MetricQ1 FY25
Total income₹444.4 cr, +21.7% YoY from ₹365 cr in Q1 FY24
EBITDA (excl. exceptional items)₹128.6 cr, margin of 28.9%, up 174 bps YoY
Gross margin66.1%, vs 55.2% in Q1 FY24 and 58.8% in Q4 FY24
Profit after tax₹98.3 cr, vs ₹62.2 cr in Q1 FY24; includes exceptional item of ₹20.6 cr from sale of surplus property
EPS₹76.6 per share
CMS revenue₹235 cr, driven by molecules in the commercial segment
Free cash flow₹50.9 cr generated in Q1 FY25
Net debt position₹110.2 cr (negative, i.e., net cash)
Capital spends₹59.1 cr in Q1 FY25
Working capital107 days to sales
Debt repaid₹8.7 cr during Q1 FY25
Capacity utilization (Unit-2 and Unit-3)90% plus
Unit-3 capacity utilization (expected FY25)30%–40%
Prime product share of portfolioLess than 30%, vs 70% about 7–8 years ago
Phase-2 pipeline additions mix60% from progression, 40% from new customer molecules (per an analyst's math)